ACTIVATION AND REGULATION OF THE HER2 AND HER4 KINASES

HER2 和 HER4 激酶的激活和调节

• 批准号: 8168826
• 负责人: RON BOSE
• 金额: $ 1.61万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-10 至 2010-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8168826
• 关键词: Biochemistry; Cancer Patient; Cellular biology; Computer Retrieval of Information on Scientific Projects Database; Drug Delivery Systems; Drug resistance; Epidermal Growth Factor Receptor; Family; Funding; Genes; Grant; Growth; Growth Factor Receptors; Human; Institution; Malignant Neoplasms; Monoclonal Antibodies; Neoplasm Metastasis; Patients; Phosphotransferases; Play; Protein Tyrosine Kinase; Proteomics; Regulation; Research; Research Personnel; Resources; Role; Signal Transduction Pathway; Source; United States National Institutes of Health; erbB-2 Receptor; extracellular; improved; kinase inhibitor; malignant breast neoplasm; member; receptor; small molecule

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Alterations of signal transduction pathways play a significant role in the growth and metastasis of human cancers. We focus on the Her2/neu receptor tyrosine kinase, a member of the EGFR growth factor receptor family, which is gene amplified and activated in about 25% of human breast cancer cases. Several drugs that target Her2/neu are used in the treatment of Her2-positive breast cancer, such as a monoclonal antibody to the extracellular portion of the receptor or small molecule kinase inhibitors, but resistance to these drugs has frequently been seen in patients. Better understanding of Her2/neu and the downstream signal transduction pathways it uses will provide improved treatment for breast cancer patients. Our lab studies signal transduction pathways in breast cancer using a variety of approaches involving biochemistry, proteomics, and cell biology.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 信号转导通路的改变在人类肿瘤的生长和转移中起重要作用。我们专注于Her 2/neu受体酪氨酸激酶，EGFR生长因子受体家族的一员，这是基因扩增和激活约25%的人类乳腺癌病例。靶向Her 2/neu的几种药物用于治疗Her 2阳性乳腺癌，例如受体细胞外部分的单克隆抗体或小分子激酶抑制剂，但在患者中经常观察到对这些药物的耐药性。更好地了解Her 2/neu及其下游信号转导通路将为乳腺癌患者提供更好的治疗。 我们的实验室研究乳腺癌的信号转导途径，使用各种方法，涉及生物化学，蛋白质组学和细胞生物学。